Healthcare & Life Sciences
Delenex Therapeutics AG
Switzerland
series-a
series-a
Stage
1
Investors
About
Delenex Therapeutics AG is a clinical-stage biopharmaceutical company that develops antibody therapeutics using its proprietary PENTBody platform to create potent and stable antibody fragments targeting diseases including oncology, Crohn's disease, and psoriasis.
Explore Delenex Therapeutics AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.